Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis

Impact of Baricitinib on Patient-Reported Skin Symptoms, Itch, and Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis and an Inadequate Response to Topical Therapies From Phase 3 Trials, BREEZE-AD1 and BREEZE-AD2

book_2 Source: AAD VMX 2020 - Poster session
calendar_today Published on Medfyle: June 2020
headphones 4 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • In two identical, independent Phase 3 trials, baricitinib monotherapy demonstrated efficacy in improving the severity of skin disease as assessed by clinician- and patient-reported outcome measures.
  • Patients with moderate-to-severe AD experienced clinically meaningful improvement in itch that occurred as early as Week 1 versus placebo.
  • Baricitinib demonstrated rapid onset of improvements in AD skin and pruritus severity and clinically meaningful improvements in quality of life. 
Presenting Author
Read more arrow_downward Hide arrow_upward

 

Peter Lio, MD
Northwestern University Feinberg School of Medicine, Chicago, IL USA

 

Peter A Lio, MD, FAAD, serves as a Clinical Assistant Professor of Dermatology and Pediatrics at the Northwestern University Feinberg School of Medicine. He is also the Founding Director of the Chicago Integrative Eczema Center and a Founding Partner of Medical Dermatology Associates of Chicago. Dr Lio attended Harvard Medical School and completed the Harvard Combined Dermatology and Acupuncture program, serving as Chief Resident. With over 100 publications and 2 textbooks, he continues to focus on atopic dermatitis, eczema, and other inflammatory skin diseases. Dr Lio is a fellow of the American Academy of Dermatology, and member of the Society for Pediatric Dermatology, Chicago Dermatological Society, and Association of Professors of Dermatology. In 2016, he received the Feinberg School of Medicine Outstanding Teacher Award Teaching Pin.

Author disclosures
Read more arrow_downward Hide arrow_upward

P. A. Lio has received grants as an investigator, and/or honoraria for lecturing, and/or consulting fees from: AbbVie, AOBiome, Arbonne, Burt's Bees, Dermavant, Dermira, Eli Lilly and Company, Exeltis, Franklin Bioscience/Altus Labs, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L'Oréal, Leo Pharma, Menlo Therapeutics, National Eczema Association, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB Pharma, Unilever, and Verrica.

This study was sponsored by Eli Lilly and Company, under license from Incyte Corporation. Medical writing assistance was provided by Cassandra Haley, PhD, CMPP, of ProScribe – Envision Pharma Group, and was funded by Eli Lilly and Company


Feedback